Biogen BIIB Acquired in-process research and development, upfront and milestone expense
Acquired in-process research and development, upfront and milestone expense at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept biib:ResearchAndDevelopmentExpenseAcquiredInProcessCost.
The source filing: Biogen’s 10-K, filed February 6, 2026.
- Filed
- Feb 6, 2026, 7:36 AM EST
- Fiscal year
- FY2025
- Accession
- 0000875045-26-000013
| --- | --- | --- | --- | | Revenue: | | | | | Cost and expense: | | | | | Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,404.2 | 2,310.4 | 2,533.4 | | Research and development | 1,778.6 | 1,980.3 | 2,445.4 | | Acquired in-process research and development, upfront and milestone expense | 471.8 | 61.5 | 16.6 | | Selling, general and administrative | 2,433.6 | 2,403.7 | 2,549.7 | | Amortization and impairment of acquired intangible assets | 515.0 | 446.7 | 240.6 | | Collaboration profit sharing/(loss reimbursement) | 290.2 | 254.4 | 218.8 | | (Gain) loss on fair value remeasurement of contingent consideration | 33.6 | 27.7 | — |
ITEM 16. FORM 10-K SUMMARY
FAQ
- What is Biogen's acquired in-process research and development, upfront and milestone expense?
- Biogen (BIIB) reported acquired in-process research and development, upfront and milestone expense of $117.95M in Q4 2025.
- How has Biogen's acquired in-process research and development, upfront and milestone expense changed year-over-year?
- Biogen's acquired in-process research and development, upfront and milestone expense increased by 667.2% year-over-year, from $15.38M to $117.95M.
- What is the long-term trend for Biogen's acquired in-process research and development, upfront and milestone expense?
- Over 2 years (2023 to 2025), Biogen's acquired in-process research and development, upfront and milestone expense has grown at a 433.1% compound annual growth rate (CAGR), from $16.6M to $471.8M.
- What does acquired in-process research and development, upfront and milestone expense mean?
- Costs associated with the acquisition of in-process research and development projects, including upfront payments and milestone payments to partners. These represent inorganic growth investments in the company's drug pipeline.
Ask your AI about Biogen's acquired in-process research and development, upfront and milestone expense.
Connect your AI assistant and compare it to peers, right in your chat.
